Characterization of adverse cutaneous effects in the setting of enfortumab vedotin for metastatic urothelial carcinoma: A retrospective review - 19/09/24
Doi : 10.1016/j.jaad.2024.06.037
Rhea Malik, MS a, b, David H. Xiang, AB a, b, Grant J. Riew, AB a, b, Stephanie Sanchez-Melendez, BS b, c, Shawn Afvari, BS b, d, Nicole R. LeBoeuf, MD, MPH b, e, Vinod E. Nambudiri, MD, MBA, MPH, EdM b, e, ⁎ 
a Harvard Medical School, Boston, Massachusetts
b Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts
c Ponce Health Sciences University, School of Medicine, Ponce, Puerto Rico
d New York Medical College, Valhalla, New York
e Department of Cutaneous Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
∗Correspondence to: Vinod E. Nambudiri, MD, MBA, MPH, EdM, Department of Dermatology, Brigham and Women's Hospital, 221 Longwood Ave, Boston, MA 02115Department of DermatologyBrigham and Women's Hospital221 Longwood AveBostonMA02115
Key words : adnexal tumor, cutaneous effects, enfortumab vedotin, SJS, TEN, urothelial cancer
| Funding sources: None. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: This study was approved by the MGB IRB, Protocol #2015P001336. |
© 2024
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 91 - N° 4
P. 753-755 - octobre 2024 Retour au numéro
Article précédent
- Hispanic patients with Merkel cell carcinoma have lower mortality compared to non-Hispanic patients in the National Cancer Database
- Winston W. Liu, Olivia S. Jew, Kristen E. Rhodin, Jay S. Lee, Georgia M. Beasley, Melodi Javid Whitley
- Pemphigus following herpes simplex infection: A global comprehensive cohort study
- Michael Kasperkiewicz, Binh T. Ngo, Gema Hernandez, Khalaf Kridin, Ralf J. Ludwig
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?